
Major Scope
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Leukemia
- Bladder Cancer
- Kidney Cancer
- Endometrial Cancer
- Oncology Case Reports
- Radiation Therapy
Abstract
Citation: Clin Oncol. 2017;2(1):1279.DOI: 10.25107/2474-1663-v2-id1279
Pivotal Role of Lymph Node Sinus Macrophages and Anti- Tumor Immune Responses in Patients with Malignant Tumors
Takuya Shiota, Yoshihiro Komohara, Yoichi Saito, Koji Ohnishi and Motohiro Takeya
Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Japan
*Correspondance to: Yoshihiro Komohara
PDF Full Text Review Article | Open Access
Abstract:
Recent progress in anti-tumor therapy has revealed the significance of anti-tumor immune responses in tumor progression and clinical course in several kinds of malignant tumor. The draining Lymph Node (LN) is an important immune system in which a number of Antigen-Presenting Cells (APCs) are present that induce rapid immune responses to foreign antigens. Recent studies have shown that LN sinus macrophages are associated with the induction of anti-tumor immunity. In some malignant tumors, a high density of CD169-positive macrophages in the draining LN sinus has been shown to be a predictive factor for better clinical prognosis. The density of CD169-positive macrophages in the LN sinus is also positively associated with the density of infiltrating T- or natural killer (NK) cells in tumor tissues. Moreover, antigen delivery targeting LN macrophages is considered to be a promising approach for vaccination. In this article, we have summarized the significance of CD169- positive LN macrophages in anti-tumor immunity, and suggested the possible correlation between macrophage phenotype and anti-tumor immunity in the draining LN.
Keywords:
CD169; Lymph node; Anti-tumor immunity; Sinus macrophage
Cite the Article:
Shiota T, Komohara Y, Saito Y, Ohnishi K, Takeya M. Pivotal Role of Lymph Node Sinus Macrophages and Anti- Tumor Immune Responses in Patients with Malignant Tumors. Clin Oncol. 2017; 2: 1279.
Journal Basic Info
- Impact Factor: 3.231**
- H-Index: 11
- ISSN: 2474-1663
- DOI: 10.25107/2474-1663
- PubMed NLM ID: 101705590